

Q3 2024



Disclaimer

The information in this presentation has been prepared by Lifecare (the “Company”). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the following limitations and provisions:

This presentation has been prepared based on information available as of the date hereof. No representation or warranty (expressor implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, none of the Company, or any advisor or any such persons’ officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this presentation. The Company is in its early stages of development and is considered to be a venture company. Venture companies in general entail a high degree of risk. It is highly recommended that potential investors seek further advice of risks associated with venture investments in general, and in particular specific risks for the Company. The information herein is subject to change, completion, supplements or amendments without notice. By relying on this presentation, you accept the risk that the presentation does not cover matters that could have been disclosed, have a more comprehensive investigation been carried out.

The presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof and may contain certain forward-looking statements. By their nature, forward- looking statements involve risk and uncertainty because they reflect the Company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. It should be understood that subsequent developments may affect the information contained in this document, which neither the Company nor its advisors are under an obligation to update, revise or affirm.

This complete presentation is for informational purposes only and does not constitute an offer to sell shares in of the company. This presentation is not a prospectus, disclosure document or offering document and does not purport to be complete.

This presentation has not been reviewed or approved by any regulatory authority or stock exchange. The (re)distribution of this presentation and/or any prospectus or other documentation into jurisdictions other than Norway may be restricted by law. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to acquire any securities offered by any person in any jurisdiction in which such an offer or solicitation is unlawful. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such restrictions.

The presentation and any purported liability in connection with it is subject to Norwegian law and is subject to the exclusive jurisdiction of the Norwegian courts.

Content

Operational review

Financial review

Progress and outlook

Q&A

Highlights

Listed on Euronext Oslo Børs 22 October

Successful completion of 12 weeks longevity test

First production of Sencell sensor based on automated processes

Strategic cooperation providing access to software for AI-based glucose analytics

Operational review



Longevity study in dogs

- **First patient completed** - the Sencell-implant was removed after 12 weeks in accordance with the regulatory approved protocol.
- **Objectives met** – operational longevity and biocompatibility validated.
- **Results as expected** - biopsies and bacteriological testing confirmed no unexpected foreign body reactions or adverse tissue responses , affirming the biocompatibility of the Sencell implant.
- **Conclusion** - the implant remained stable throughout the 12-week period.

Progress towards automated production

- The most critical steps of the production has been automated.
- The critical steps include 3D-printing of pressure sensors, and filling and sealing of the sensor.
- Identified opportunities to further optimize product and production tolerances, to meet the highest quality standards.
- Anticipate advancements in production consistency by the end of 2024, with validations expected early 2025.
- Expect launch of product in veterinary market in first half of 2025.

Study protocol


- Draft protocol for long-term human clinical study finalized.
- Significant advancement towards the next phase: CE clinical study for regulatory approval.
- Ongoing tender to Contract Research Organizations.
- Identify clinical study sites.

Cooperation with OneTwo Analytics

- Strategic partnership with the Swedish company, specializing in diabetes data analytics.
- Access to AI and ML-based software for patient self-monitoring and interpretation of CGM data.
- Licence to commercialize software in the veterinary market.

Financial review





- Operating expenses of NOK 22 million in line with expectations
- Capex of NOK 8 million in equipment related to automated production
- Net cash flow of NOK 25 million
- Cash position of NOK 76 million at quarter end

Progress

	Studies	Regulatory compliance	Production and market launch
2022	<p>Successful in-vitro testing confirming functionality of miniaturized sensors</p> <p>Proof-of-concept in humans</p>	<p>Approval for accuracy study LFC- SEN-001</p>	<p>Production location secured</p>
2023	<p>In-human study (LFC-SEN-001) confirming clinical accuracy in line with gold standard</p> <p>Longevity study of the Sencell with operational lifetime of more than 172 days</p>	<p>ISO 9001 and ISO 13485 certified</p> <p>Norwegian Medicine Agency confirms no specific regulation for Sencell medical device for animals in Norway</p> <p>Approval for longevity study in dogs (LFC-SEN-002)</p>	<p>Preparations for a automated production</p>
2024	<p>In-dogs longevity study (LCF-SEN-002) confirming operational lifespan</p> <p>Preparations for LFC-SEN-003</p>	<p>CE approved device to remove subdermal implants</p>	<p>Pilot production</p> <p>Key steps in automated production</p>
2025	<p>In-dogs longevity, biocompatibility and data accuracy study (LFC-SEN-002)</p> <p>Clinical study (LFC-SEN-003) confirming operational efficiency</p>	<p>Build technical file to claim CE-mark for Sencell for the human market</p>	<p>Product launch for veterinary market</p> <p>Automated production</p>


Outlook

- Advancing production consistency and continue progress towards automated production.
- Continuation of study in dogs to confirm longevity, biocompatibility and data accuracy.
- Preparing for the clinical study LFC-SEN-003, the foundation to claim the CE-mark for Sencell for the human market.



Q3 2024 report is available
for download at

lifecare.no/investor/reports-presentations/



LIFECARE